Similarly, antibodies against PD-1/PD-L1 release the brake mechanism provided by the interaction between PD-1/PD-L1 signaling, allowing T lymphocytes to remain active despite the inhibitory molecules expressed by the tumor. Here, CD274 is linked to neoplasm.